Led · Series B · May 2019

Concentric Analgesics is a clinical-stage company focused on developing and commercializing novel, non-opioid pain therapeutics. Its lead candidate, vocacapsaicin (CA-008), is a proprietary prodrug that rapidly converts to capsaicin, a TRPV1 agonist, and is intended to provide long-lasting pain relief after a single local administration. Vocacapsaicin has shown Phase 2 efficacy across surgical models and has received Fast Track and Breakthrough Therapy designations from the U.S. FDA. The company intends to use the proceeds of its recent financing to fund registration-enabling Phase 3 development and to move toward an NDA submission. Concentric also has two additional active programs targeting osteoarthritis pain and chronic refractory pain. The company positions vocacapsaicin as a potential non-opioid standard of care for postsurgical pain relief. Concentric Analgesics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics. Its lead product candidate, CA-008, is a first-in-class TRPV1-agonist prodrug that rapidly converts to capsaicin and is designed to provide long-lasting pain relief after a single local administration. CA-008 is in Phase 2 clinical studies and has received both Breakthrough Therapy and Fast-Track designations from the U.S. Food and Drug Administration. The company also maintains a pipeline of TRPV1-agonist prodrugs targeting chronic refractory pain and osteoarthritis, with three active programs. Concentric intends to use the new proceeds to advance CA-008 into late-stage clinical development and to continue development of its broader pipeline. The company is headquartered in San Francisco, California.